Mastek named supplier on UK’s Digital Capability for Health 2 Framework

IT company Mastek Ltd on Thursday (March 6) said it has been named a supplier on the UK Crown Commercial Service’s RM6345 Digital Capability for Health 2 (DCfH 2) framework. This single-lot agreement supports digital transformation initiatives in the health and social care sectors.The DCfH 2 framework will operate for the next three years, with the option for a one-year extension. This framework will provide Health and Social Care organisations with access to Mastek’s expertise in delivering agile development services for new digital solutions, supporting existing products and services, and offering data management services – including health data collection, processing, and distribution.
Through DCfH 2, Health and Social Care organisations can procure Digital, Data, and Technology (DDaT) resources to support digital transformation programmes across the UK public health and social care. This includes both the development of new digital solutions and the maintenance of existing services.
Also Read: Mastek Q3 Results | Net profit rises 27% to ₹95 crore, revenue up 11%; dividend declaredThis single-lot agreement under the UK Crown Commercial Service’s RM6345 Digital Capability for Health 2 framework encompasses five key service provisions.

It includes Development and Operations (DevOps) for continuous improvement of live services, Digital Definition Services to support discovery and alpha phase projects, and Build and Transition Services for service development through beta and live phases.Additionally, it covers end-to-end development services, offering full lifecycle support from discovery to live, as well as data management services for data collection, processing, analysis, and governance.

Also Read: IT services tariffs difficult to implement, pose no immediate threat: Mastek

The agreement aims to support the ongoing digitisation and modernisation of the NHS digital infrastructure, aligning with the UK Government’s plans for the NHS. Mastek continues to play a crucial role in supporting the provision of healthcare services and enabling faster, safer, and more convenient

patient care.

Shares of Mastek Ltd ended at ₹2,376.65, up by ₹56.00, or 2.41%, on the BSE.